In partnership with
The Bottom Line Upfront 💡
$CI ( ▼ 0.29% ) Five sixths of Cigna's revenue now comes from Evernorth, its pharmacy and health services arm, not from selling insurance. Earnings per share grew 19% in the first half and the stock went nowhere, because the market is pricing a regulatory haircut on pharmacy benefit managers. That is the entire debate.
Since We Last Called It 🔁
Last look | The call | Price then | Price now | Since then |
|---|---|---|---|---|
April 2026 | Significantly undervalued | $280 | $275-$290 | +4% (S&P 500 +7%) |
The call went roughly nowhere against the index, which is the honest description of five months of drift. The business did its part: earnings per share rose 19% in the first half. The multiple absorbed all of it. Our last guide claimed 360% to 687% upside, and that number should never have run: it implied a fair value above $1,200 a share for a company earning $6.4B. See Layer 4 for what the model should have said.
Sponsorship
Hire anyone, anywhere — compliant in under 3 days
Found the right person, but they’re in a country where you don’t have an entity? Setting one up can take months and significant cost.
Remote removes that barrier by becoming the legal employer through our own entities — handling compliant contracts, local benefits, tax setup, and onboarding for you. In fact, an employee is onboarded to Remote every 7 minutes.
Once they’re hired, the same in-house teams that support employment locally also run payroll — so you’re not bouncing between disconnected providers. Less setup, less complexity, and less time between finding the right person and getting them started.
Strata Layers Chart
Layer 1: The Business Model 🏛️
Cigna is two companies wearing one ticker, and the smaller one is the one everybody thinks of.
Evernorth ($235B of 2025 revenue, up 18.6% ↗️) is the pharmacy business, and it is 83% of the company. At its heart sits Express Scripts, a pharmacy benefit manager. A PBM sits between drugmakers, insurers and pharmacies: it decides which drugs are on a health plan's approved list, negotiates rebates from manufacturers in exchange for that placement, and processes the claim when you collect the prescription. Evernorth also runs mail-order and specialty pharmacies, which dispense the expensive complex drugs that now drive most of American pharmaceutical spending.
Cigna Healthcare ($47.4B, essentially flat) is the insurance business people picture: employer health plans, mostly for large companies, plus dental, vision and international coverage.
The revenue figure is misleading, and this is the single most important thing to understand. Evernorth books the full cost of every drug it dispenses as revenue, then pays nearly all of it straight back out. That is why $282B of revenue produces a 2% operating margin. Cigna is a high-volume pass-through with a small toll attached, so judge it on profit dollars and cash, never on margin.
Key Takeaway: Cigna is a pharmacy services company with an insurance division attached, and its revenue line is mostly other people's drug costs flowing through.
Layer 2: Category Position 🏆
Three PBMs process roughly 80% of American prescriptions: Express Scripts, UnitedHealth's OptumRx, and CVS Health's Caremark. That is an oligopoly with enormous scale advantages, and it is precisely why regulators keep circling.
On the insurance side Cigna is the smallest of the big national players by choice. In 2025 it took $2.4B of proceeds from divesting businesses, having exited Medicare Advantage, the government-funded plans for older Americans where rivals have absorbed heavy losses on rising medical costs. Walking away before that sector's margin problems worsened looks, in hindsight, like good judgement.
The threat is legislative. Proposals to separate PBMs from insurers, to force rebates through to patients, or to mandate transparent pricing all attack the same profit pool. Cigna has responded by promoting rebate-free pricing models, which is either getting ahead of the rules or conceding the argument, depending on your view.
Key Takeaway: Cigna holds a third of an oligopoly that is highly profitable and highly disliked, and that tension is what the share price is arguing about.
Layer 3: Show Me The Money! 📈
Growth is real and it is all Evernorth. Q1 2026 revenue was $68.5B, up 4.6% ↗️, and Q2 was $71.7B, up 6.6% ↗️. Specialty pharmacy volume and higher-cost drugs drive the line. Cigna Healthcare revenue was flat year on year at $47.4B, shrunk by the Medicare exit and grown back by employer pricing.
Earnings are compounding faster than revenue. First-half diluted earnings per share came to $12.55 against $10.56 a year earlier, up 18.8% ↗️. Trailing twelve month earnings are roughly $24 a share. Part of that is operations, part of it is arithmetic: the diluted share count fell from 283M to 264M over six quarters.
Cash conversion is excellent. Operating cash flow was $9.6B in 2025 against just $1.2B of capital spending, leaving $8.4B of free cash. Trailing free cash flow near $9.1B is a yield around 12%. This business owns claims systems and mail-order pharmacies rather than hospitals, so it needs almost no capital to grow.
Capital returns are heavy. Cigna spent $3.6B on buybacks in 2025 and $7.0B in 2024, plus $1.6B of dividends, roughly $6.06 a share for a 2.1% yield.
Net debt is $25.6B, about 2.2 times EBITDA, which is unremarkable for a company throwing off $9B a year.
Key Takeaway: Twelve times earnings and a 12% cash yield for a business growing profit at 19% is either an opportunity or an accurate discount for regulatory risk.
Layer 4: Long-Term Valuation (DCF Model) 💰
The Verdict: Undervalued, with a Regulatory Asterisk 🤔
Scenario | Fair Value | vs Current Price ($275-$290) |
|---|---|---|
Conservative (PBM reform bites) | $220 | -22% |
Base Case | $420 | +49% |
Optimistic | $570 | +102% |
Key assumptions:
Conservative assumes reform cuts free cash flow to $7B with 1% growth, discounted at 9.5%. This is the scenario the market is partially pricing.
Base case takes $8.7B of free cash flow growing 2% at 8.5%, roughly today's business continuing.
All three subtract $25.6B of net debt across 264M shares.
What the last guide got wrong. A 360% to 687% upside range implied a fair value above $1,200 a share and a market capitalisation north of $340B. No discounted cash flow model that subtracts net debt and applies a real discount rate produces that on $9B of free cash flow. The honest range is the one above, and it is still wide, because the regulatory outcome genuinely is.
One-line take: The cash flow says cheap and the legislature says maybe, and you are being paid about 12% a year to wait for the answer.
Layer 5: What Do We Have to Believe? 📚
Bull Case 🚀
PBM reform lands as disclosure rules rather than structural separation, and the profit pool survives largely intact
Evernorth keeps compounding on specialty pharmacy, where drug costs are rising fastest and scale matters most
Buybacks at twelve times earnings keep converting $9B of annual cash into meaningful per-share growth
Bear Case 🐻
Legislation forces rebates through to patients or splits PBMs from insurers, removing a core profit mechanism
Employer health costs keep rising faster than premiums, squeezing the insurance side that was supposed to be the stable half
Customer concentration bites: large PBM contracts are few, enormous, and periodically go out to tender
The Bottom Line: Cigna earns a great deal of money from a structure that a meaningful number of legislators would like to dismantle. Twelve times earnings with a 12% free cash flow yield is the market's honest price for that uncertainty, not an oversight. Own it if you think reform lands softly. Do not own it expecting the discount to close for reasons unrelated to Washington.
Layer 6: What to Watch 👀
PBM legislation. Disclosure requirements are survivable. Forced structural separation of PBM from insurer is not, at anything like this valuation.
Evernorth revenue growth below 10%. It has been running near 19%. Deceleration would remove the only genuine growth engine.
Medical cost ratio in Cigna Healthcare. The share of premiums paid out in claims. Rising means employer pricing is not keeping up with medical inflation.
Buyback pace. It fell from $7.0B in 2024 to $3.6B in 2025. Another sharp drop suggests management sees a use for the cash, or a reason to hold it.
Large contract renewals. A single lost PBM client can move billions of revenue. Watch commentary on retention rates at renewal season.
AI-written, human-approved
Disclaimer: This guide is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer or solicitation to buy or sell any securities. The information contained in this report has been obtained from sources believed to be reliable, but StrataFinance does not guarantee its accuracy, completeness, or timeliness.